Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
AACR 2024 – Medicenna looks for a cytokine renaissance
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
Gritstone fails to convince
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
ASCO-GI – Leap falters again
Randomised data will be needed to answer lingering questions about DKN-01.
ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
